Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-X-C motif chemokine ligand 10 messenger RNA lipid nanoparticle
- Development stage
- Preclinical
- Lead developer
- West Virginia University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
C-X-C motif chemokine ligand 10 messenger RNA lipid nanoparticle (Cxcl10 mRNA-LNP) is an investigational mRNA-based immunotherapy designed to modulate the tumor microenvironment. It consists of messenger RNA encoding the CXCL10 chemokine (also known as IP-10) encapsulated within a lipid nanoparticle (LNP) delivery system. Upon intramuscular administration, the mRNA is translated into CXCL10 protein, which acts as a potent chemoattractant for activated T cells by signaling through the CXCR3 receptor. This 'genetic adjuvant' approach is intended to increase the infiltration of CD8+ cytotoxic T cells into tumors, particularly in immunotherapy-resistant cancers like melanoma. Preclinical studies have demonstrated that Cxcl10 mRNA-LNP can significantly reduce tumor volume and metastasis when used in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies.
- Other names
- CXCL10 mRNA-LNPCXCL-10 mRNA-LNPCXCL 10 mRNA-LNPIP-10 mRNA-LNPIP10 mRNA-LNPIP 10 mRNA-LNP
02
Targets
CCR3 (C-C chemokine receptor type 3)
Beyond the preview
Go deeper on C-X-C motif chemokine ligand 10 messenger RNA lipid nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-X-C motif chemokine ligand 10 messenger RNA lipid nanoparticle.